Cyteir Therapeutics executive buys $342k in company stock
CYT
0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
Cyteir Therapeutics, Inc. (NASDAQ:CYT), a company specializing in pharmaceutical preparations, has seen notable insider activity as reported in a recent SEC filing. Braden Michael Leonard, a significant shareholder, made a substantial purchase of company stock.
On March 18, 2024, Leonard acquired 113,777 shares of Cyteir Therapeutics at a price of $3.01 per share, amounting to a total investment of approximately $342,468. This transaction has increased his direct and indirect holdings to a total of 3,483,464 shares. It is important to note that the shares acquired are held indirectly through BML Investment Partners, L.P., with BML Capital Management, LLC acting as the general partner. Leonard, who is the managing member of BML Capital, has investment and voting control over these shares.
Investors often monitor insider purchases as they can indicate executives’ confidence in the company’s future prospects. The acquisition by Leonard could be seen as a positive signal for Cyteir Therapeutics, as significant shareholders continue to invest in the company’s stock.
For further details on these transactions, investors can refer to the full SEC Form 4 filing.
InvestingPro Insights
As investors scrutinize the insider buying activity at Cyteir Therapeutics, Inc. (NASDAQ:CYT), several financial metrics from InvestingPro provide a broader context for evaluating the company’s current market position. The adjusted market capitalization of Cyteir Therapeutics stands at $108.69 million, reflecting the company’s valuation in the market. Despite challenging conditions, as indicated by a negative P/E ratio of -3.23 currently and -3.75 for the last twelve months as of Q3 2023, the company’s price/book ratio of 0.87 suggests that the stock is trading below the company’s book value, which could be a point of interest for value investors.
The company’s operating performance, with an adjusted operating income of -$33.95 million and an EBITDA of -$33.41 million for the same period, shows that Cyteir Therapeutics is currently operating at a loss. However, the EBITDA growth rate of 32.28% indicates some operational improvements. Additionally, the 1 Year Price Total Return as of Y2024.D79 is notably high at 81.33%, which could be a reflection of the market’s long-term confidence in the company’s growth potential.
InvestingPro Tips suggest that the recent insider purchase by Braden Michael Leonard might align with the company’s fair value estimates. The InvestingPro Fair Value is calculated at $3.44, slightly above the current analyst target of $3.00, possibly indicating room for growth. For investors seeking more in-depth analysis, InvestingPro offers a range of additional tips—there are 15 more InvestingPro Tips available for Cyteir Therapeutics that can provide further guidance on investment decisions.
Investors looking to gain a comprehensive understanding of Cyteir Therapeutics’ financial health and future prospects can benefit from the insights available on InvestingPro. By using the coupon code PRONEWS24, investors can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription to access these valuable resources.
